Masayuki Inoue1, Hiroshi Nakagomi2, Haruka Nakada2, Kazushige Furuya2, Kou Ikegame2, Hideki Watanabe2, Masao Omata3,4, Toshio Oyama5. 1. Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan. inoue-bfgz@ych.pref.yamanashi.jp. 2. Department of Surgery, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, Japan. 3. Department of Internal Medicine, Yamanashi Prefectural Central Hospital, Kofu, Japan. 4. University of Tokyo, Tokyo, Japan. 5. Department of Pathology, Yamanashi Prefectural Central Hospital, Kofu, Japan.
Abstract
BACKGROUND: Invasive lobular carcinoma (ILC) is known to be the second most common histological type following invasive ductal carcinoma (IDC). Definitive clinical features of ILC are controversial. METHODS: We retrospectively analyzed a cohort of 330 patients with metastatic breast cancer, 303 of IDC, 19 of ILC, and 8 of others. We compared the patient age and tumor-node-metastasis factors, disease-free survival (DFS), estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expression at the primary site between ILC and IDC. We then selected the patients in the ER+ or PR+/HER2- subtype specifically and compared sites of recurrence, and the survival curve starting from the point of development of metastatic disease. RESULTS: The clinical stage was significantly higher in the ILC patients than in the IDC (p = 0.001). The mean (±SD) of DFS for the ILC and IDC patients was 2.6 ± 0.6 and 2.4 ± 0.3 years, respectively, with no significant difference (p = 0.18). However, the hormone receptor status was same between both groups; the rate of HER2 positivity was significantly lower in the ILC group (0%) than in the IDC group (16.2%) (p = 0.05). In ER+ or PR+/HER2- subtype, the mean DFS for the ILC and IDC was 2.9 ± 0.6 and 3.1 ± 0.3 years, and the median survival time after the recurrence for ILC and IDC patients was 4.2 ± 0.7 and 5.6 ± 0.7 years, respectively, with no significant difference (p = 0.77). The frequency of lung metastases was significantly lower in the ILC group (6.3%) than in the IDC group (53.7%) (p < 0.01), while the frequency of peritoneal metastases was significantly higher in the ILC group (68.8%) than in the IDC group (1%) (p = 0.00). Of note, the prognosis after the diagnosis of peritoneal metastases was poor, with a median survival time of 19 ± 9 months and resistance to hormone therapy. CONCLUSIONS: The extremely high rate (68.8%) of peritoneal metastases was observed in long-term follow-up for the metastatic breast cancer patients with ILC. We need to reveal the definitive feature of ILC and develop new therapeutic strategies to prevent the dissemination of ILCs.
BACKGROUND:Invasive lobular carcinoma (ILC) is known to be the second most common histological type following invasive ductal carcinoma (IDC). Definitive clinical features of ILC are controversial. METHODS: We retrospectively analyzed a cohort of 330 patients with metastatic breast cancer, 303 of IDC, 19 of ILC, and 8 of others. We compared the patient age and tumor-node-metastasis factors, disease-free survival (DFS), estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) expression at the primary site between ILC and IDC. We then selected the patients in the ER+ or PR+/HER2- subtype specifically and compared sites of recurrence, and the survival curve starting from the point of development of metastatic disease. RESULTS: The clinical stage was significantly higher in the ILC patients than in the IDC (p = 0.001). The mean (±SD) of DFS for the ILC and IDC patients was 2.6 ± 0.6 and 2.4 ± 0.3 years, respectively, with no significant difference (p = 0.18). However, the hormone receptor status was same between both groups; the rate of HER2 positivity was significantly lower in the ILC group (0%) than in the IDC group (16.2%) (p = 0.05). In ER+ or PR+/HER2- subtype, the mean DFS for the ILC and IDC was 2.9 ± 0.6 and 3.1 ± 0.3 years, and the median survival time after the recurrence for ILC and IDC patients was 4.2 ± 0.7 and 5.6 ± 0.7 years, respectively, with no significant difference (p = 0.77). The frequency of lung metastases was significantly lower in the ILC group (6.3%) than in the IDC group (53.7%) (p < 0.01), while the frequency of peritoneal metastases was significantly higher in the ILC group (68.8%) than in the IDC group (1%) (p = 0.00). Of note, the prognosis after the diagnosis of peritoneal metastases was poor, with a median survival time of 19 ± 9 months and resistance to hormone therapy. CONCLUSIONS: The extremely high rate (68.8%) of peritoneal metastases was observed in long-term follow-up for the metastatic breast cancerpatients with ILC. We need to reveal the definitive feature of ILC and develop new therapeutic strategies to prevent the dissemination of ILCs.
Entities:
Keywords:
Invasive lobular carcinoma (ILC); Metastatic breast cancer; Peritoneal metastases
Authors: Aju Mathew; Padma S Rajagopal; Vipin Villgran; Gurprataap S Sandhu; Rachel C Jankowitz; Mini Jacob; Margaret Rosenzweig; Steffi Oesterreich; Adam Brufsky Journal: Geburtshilfe Frauenheilkd Date: 2017-06-28 Impact factor: 2.915
Authors: J Asher Jenkins; Schelomo Marmor; Jane Yuet Ching Hui; Heather Beckwith; Anne H Blaes; David Potter; Todd M Tuttle Journal: Breast Cancer Res Treat Date: 2021-10-29 Impact factor: 4.872
Authors: Alicia Okines; Tazia Irfan; Bernice Asare; Kabir Mohammed; Peter Osin; Ashutosh Nerurkar; Ian E Smith; Marina Parton; Alistair Ring; Stephen Johnston; Nicholas C Turner Journal: Breast Cancer Res Treat Date: 2022-02-04 Impact factor: 4.872
Authors: Philippe Debourdeau; Marc Espié; Sylvie Chevret; Joseph Gligorov; Antoine Elias; Pierre François Dupré; Kristell Desseaux; Issa Kalidi; Stephane Villiers; Sylvie Giachetti; Corinne Frere; Dominique Farge Journal: Cancer Med Date: 2017-10-04 Impact factor: 4.452